Cav3.2 calcium channels are important
mediators of nociceptive
signaling in the primary afferent pain pathway, and their expression
is increased in various rodent models of chronic pain. Previous work
from our laboratory has shown that this is in part mediated by an
aberrant expression of deubiquitinase USP5, which associates with
these channels and increases their stability. Here, we report on a
novel bioactive rhodanine compound (II-1), which was identified in
compound library screens. II-1 inhibits biochemical interactions between
USP5 and the Cav3.2 domain III-IV linker in a dose-dependent manner,
without affecting the enzymatic activity of USP5. Molecular docking
analysis reveals two potential binding pockets at the USP5-Cav3.2
interface that are distinct from the binding site of the deubiquitinase
inhibitor WP1130 (a.k.a. degrasyn). With an understanding of the ability
of some rhodanines to produce false positives in high-throughput screening,
we have conducted several orthogonal assays to confirm the validity
of this hit, including in vivo experiments. Intrathecal delivery of
II-1 inhibited both phases of formalin-induced nocifensive behaviors
in mice, as well as abolished thermal hyperalgesia induced by the
delivery of complete Freund’s adjuvant (CFA) to the hind paw.
The latter effects were abolished in Cav3.2 null mice, thus confirming
that Cav3.2 is required for the action of II-1. II-1 also mediated
a robust inhibition of mechanical allodynia induced by injury to the
sciatic nerve. Altogether, our data uncover a novel class of analgesicswell
suited to rapid structure–activity relationship studiesthat
target the Cav3.2/USP5 interface.